| Drug General Information |
| Drug ID |
D0A9HM
|
| Former ID |
DNC003687
|
| Drug Name |
1-(2-Oxo-2-p-tolyl-ethyl)-1H-indole-2,3-dione
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C17H13NO3
|
| Canonical SMILES |
CC1=CC=C(C=C1)C(=O)CN2C3=CC=CC=C3C(=O)C2=O
|
| InChI |
1S/C17H13NO3/c1-11-6-8-12(9-7-11)15(19)10-18-14-5-3-2-4-13(14)16(20)17(18)21/h2-9H,10H2,1H3
|
| InChIKey |
PJQULSIUMHBSSF-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Plasminogen |
Target Info |
Inhibitor |
[1]
|
|---|
|
KEGG Pathway
|
Neuroactive ligand-receptor interaction
|
|
Complement and coagulation cascades
|
|
Staphylococcus aureus infection
|
|
Influenza A
|
|
PANTHER Pathway
|
Blood coagulation
|
|
Plasminogen activating cascade
|
|
Pathway Interaction Database
|
Angiopoietin receptor Tie2-mediated signaling
|
|
p75(NTR)-mediated signaling
|
|
amb2 Integrin signaling
|
|
Syndecan-4-mediated signaling events
|
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
|
PathWhiz Pathway
|
Coagulation
|
|
Reactome
|
Platelet degranulation
|
|
Degradation of the extracellular matrix
|
|
Activation of Matrix Metalloproteinases
|
|
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
|
|
Dissolution of Fibrin Clot
|
|
WikiPathways
|
Complement and Coagulation Cascades
|
|
Human Complement System
|
|
Regulation of Insulin-like Growth Factor (IGF) Transport and Uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
|
|
Activation of Matrix Metalloproteinases
|
|
Blood Clotting Cascade
|
|
Dissolution of Fibrin Clot
|
|
Folate Metabolism
|
|
Vitamin B12 Metabolism
|
|
Selenium Micronutrient Network
|
| References |
| REF 1 | Bioorg Med Chem Lett. 2000 Nov 20;10(22):2501-4.Parallel synthesis of isatin-based serine protease inhibitors. |
|---|
